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Introduction
Cell lines are widely used in many aspects of laboratory
research and particularly as in vitro models in cancer
research. They have a number of advantages; for example,
they are easy to handle and represent an unlimited self-
replicating source that can be grown in almost infinite
quantities. In addition, they exhibit a relatively high degree
of homogeneity and are easily replaced from frozen stocks
if lost through contamination. However, there are disad-
vantages. Cell lines are prone to genotypic and pheno-
typic drift during their continual culture. This is particularly
common in the more frequently used cell lines, especially
those that have been deposited in cell banks for many
years. Subpopulations may arise and cause phenotypic
changes over time by the selection of specific, more
rapidly growing clones within a population. This was high-
lighted by Osborne and colleagues [1], who demonstrated
many discrepancies in the most commonly used breast
cancer cell line, namely MCF-7, obtained from different
laboratories. As well as variations in cell growth rate,
changes were observed in hormone receptor content,
karyotype and clonogenicity, despite the cells appearing
morphologically identical. Using 24-colour fluorescent
in situ hybridization, this observation has again come to
the fore, with MCF-7 cells from different UK laboratories
showing markedly different karyotypes [2].
Thus, there is substantial evidence not only for intralabora-
tory cell line heterogeneity within established cell lines, but
also for drift away from the phenotype of the originating
tumour. This is a cause for serious concern, especially if
such cell lines are to be regarded as valid models for eval-
uating the pathobiology of breast cancer and/or the likely
response to novel drug therapies.
‘False’ cell lines
Another important consideration, which has largely been
ignored over the years, is the concept of ‘false’ cell lines.
This was first highlighted over 20 years ago by the demon-
stration that a large number of cell lines were contami-
nated with HeLa cells [3]. HeLa was the first cell line to be
developed in 1952, from a glandular cancer of the cervix
[4]. The HeLa cell line has since become notorious as a
cross-contaminant of many other cell lines.
The increasing misuse of ‘false’ cell lines has recently
come to light in the literature, with the observation that of
252 new cell lines deposited at the German Cell Line
Bank, nearly one-fifth of these (18%) were found to be
cross-contaminants [5,6]. It has been suggested that
many referees and editors of journals are unaware of the
extent of this cross-contamination problem. Thus, for cell
lines to be used as models in a meaningful way, it is imper-
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ative that they are well characterized before embarking on
a programme of research.
A potential answer to this problem would be for all jour-
nals to demand that any cell lines be thoroughly identified
and characterized before the publication of results. This
can be conducted in number of ways, including HLA
typing, karyotyping, isoenzyme typing and DNA fingerprint-
ing. However these tests are difficult to reproduce and
can be costly. The use of short tandem repeat (STR) pro-
filing has been proposed as a potentially easier, cheaper,
and more reliable and reproducible way of screening cell
lines [7]. First developed for forensic use, STR profiling
can also be used to validate cell lines by employing a stan-
dard set of STR primers to detect a number of polymor-
phic STR loci using commercially available oligonucleotide
primers [7]. Analysis of 253 cell lines from a number of
sources worldwide using STR profiling resulted in a highly
accurate numerical code, akin to a cell line specific
‘barcode’ that relates to the length of specific polymerase
chain reaction products amplified at each locus [7]. This
can provide a universal reference standard against which
human cell lines may be compared. Since the late 1960s,
researchers have recognized the importance of testing
cultured cells for possible mycoplasma infection, which
can invalidate results; in the 21st century, STR profiling
now deserves equal recognition and should become a
routine procedure in research laboratories.
Long-established breast cancer cell lines
Apart from MCF-7, which was derived in the Michigan
Cancer Foundation (from which it derives its name) in
1973 from a pleural effusion [8] and which is the most
commonly used breast cancer cell line in the world, a
number of other cell lines are routinely used as breast
cancer models. Some of the most common are shown in
Table 1 [9–14], along with the number of times they have
been cited in scientific literature over a defined period of
time. However, apart from the pitfalls described above in
cell line work, as illustrated in Table 1 most of these long
established breast cancer cell lines in current use are not
derived from primary breast tumours, but from tumour
metastases, especially aspirates or pleural effusions. This
means that the majority of such cell lines are derived from
more aggressive and often metastatic tumours, rather than
the primary lesion. This is clearly unrepresentative of the
diverse types of tumour, which are reflected by the spe-
cific types, the various grades or stages, and indications
for tumour progression that are observed in primary breast
cancer. Thus, research that relies on such lines will be
biased toward more rapidly progressive types of breast
carcinoma and to late-stage disease, rather than lower
grade and earlier stage breast cancers. For these reasons
it would be more clinically relevant to use cells that are
derived directly from a primary tumour, particularly
because most drug therapies are directed against these.
Recently established breast cancer cell lines
Apart from the more traditional breast cancer cell lines
detailed above, a number of novel breast cancer cell lines
have been established and characterized in recent years
[15–18]. Some of these have the advantage of being
established from the primary lesion rather than from a
distant metastasis. Establishing these new lines has been
a lengthy process that requires patience, with most taking
several months to meet the recognized criteria of a bona
fide continuous cell line. This includes altered cytomor-
phology, increased growth, reduced serum dependency,
increased clonogenicity, a tendency toward anchorage-
independent growth, changes in ploidy, tumourigenicity in
nude mice and an infinite lifespan [19].
Two studies have compared the characteristics of recently
established breast cancer cell lines with those of the
Table 1
Origins of a number of commonly used breast cancer cell lines and their citation frequency from 1 January 1990 to 31 December
2002, according to PubMed
Cell line Origin Age (years) Pathology Citations Reference
BT20 Breast 74 Invasive ductal carcinoma 260 [9]
MDA-MB-231 Pleural effusion 51 Adenocarcinoma 1157 [10,11]
MDA-MB-435 Pleural effusion 31 Invasive ductal carcinoma 292 [11]
MDA-MB-468 Pleural effusion 51 Adenocarcinoma 223 [11]
MCF-7 Pleural effusion 69 Invasive ductal carcinoma 5774 [8]
SkBr3 Pleural effusion 43 Adenocarcinoma 203 [12]
T47D Pleural Effusion 54 Invasive ductal carcinoma 866 [13]
ZR75.1 Ascites 47 Invasive ductal carcinoma 590 [14]91
tumour from which they were isolated [17,18]. Good con-
cordance was observed in terms of morphology (87%),
immunohistochemical analysis of oestrogen and proges-
terone receptors (87% and 73%, respectively), HER2/neu
(93%), p53 (100%) and allelic loss (82–100%). A related
study used comparative genomic hybridization to deter-
mine recurrent genetic alterations in 38 breast cancer cell
lines, and the extent to which these cell lines resembled
uncultured tumours [20]. As well as more recently estab-
lished cell lines, that study also included some of the long
established cell lines detailed in Table 1. The most
common chromosomal gains were seen in 1p, 1q, 3q, 5p,
7p, 7q, 8q, 17q, 20p and 20q, with losses observed in 1p,
4p, 8p, 10q, 11q, 18p, 18q, 19p, Xp and Xq. An average
of 19 genetic changes was observed, with nine losses
and 10 gains per cell line, which is 2.5 more alterations
per cell line as compared with tumours; however, the most
prominent alterations were the same. A number of high-
level amplifications were also observed in the cell lines
that were previously reported in breast tumours. Although
several recurrent and high-level amplifications were
observed in these cell lines, some of which have also been
noted in uncultured breast cancers (e.g. 1q32, 8p11,
8q23, 11q13, 17q23, 17q24 and 20q13), many amplifi-
cation sites were novel (e.g. 1p13, 7q21, 7q31, 9p23 and
11p13). These may represent changes associated with
culture  in vitro. Although no direct comparisons were
made between chromosome changes in traditional cell
lines versus those that were recently established, the
10 most highly upregulated genes were observed in three
of the former (MCF-7, SKBr3, ZR75.1wt) and only one of
the latter (SUM52). Notably, however, SUM52 was
derived from a pleural effusion rather than directly from a
primary breast lesion [21].
Another study used comparative genomic hybridization to
identify chromosomal change in a panel of 11 novel and
well characterized breast cancer cell lines established
from primary tumours [22]. This showed several recurrent
chromosomal gains at 1q, 3q and 8q. These findings are
consistent with those in fresh tumour material [23]. Thus,
these more recently established cell lines are potentially
more representative of breast cancer as a whole, because
many different tumour types, grades and stages can be
represented. Clearly, these new cell lines are attractive
models, and because some of these have been deposited
in the recognized cell banks (e.g. American Type Culture
Collection; http://www.atcc.org) they are now commonly
available to breast cancer researchers.
Primary cell culture
A viable alternative to using cell lines, either traditional or
more recently derived, is to prepare primary cultures
derived directly from tumours. This has a number of advan-
tages. Not only are cells directly isolated from the tumour
site, but also detailed pathology is available to allow the
characteristics of the culture to be compared with those of
the original tumour. Broadly speaking, such cultures can
be established either as explants, in which mixed cell pop-
ulations grow out from small fragments of tissue, or as
enriched populations of defined cell types, the latter being
more desirable.
Explant culture
Initial attempts at primary culture of breast tumours met
with limited success because of overgrowth of epithelial
cells with stromal fibroblasts, aptly described as ‘weeds in
the tissue culturist’s garden’ [24]. Fibroblasts quickly
adapt to in vitro conditions by proliferating rapidly and out-
growing their slower epithelial neighbours. This is a partic-
ular problem with explants, and so researchers have
turned to separating enriched populations of defined cell
types to overcome this.
Culture of individual cells
The most straightforward of these methods is the spillage
technique, originally described over 40 years ago [25].
This involves cutting the tumour and collecting the cells,
which spill out from the cut surface. This has been used
successfully in recent years by McCallum and Lowther
[16], who were able to establish 10 new cell lines from
135 unselected primary breast tumours.
Most other published protocols have relied on enzymatic
dispersal of tumour fragments following mechanical disag-
gregation of tumour fragments. A partial enzymatic degra-
dation of tumour stroma for up to 6 hours has been
described [26] and permits the enrichment and expansion
of breast epithelial cells in vitro. Approximately 66% of
samples gave rise to tumour epithelial cells with prolifera-
tive capacity. The same group described a sandwich
culture [27], in which dissociated breast tumour cells are
sandwiched between two glass microscope slides. The
slides are immersed in culture medium, which fills the gap
between the two slides, creating a natural diffusion gradi-
ent for oxygen, nutrients and metabolic waste products.
Under these conditions only malignant cells can survive,
displaying the cytokeratin (CK) profile associated with
lumenal epithelia, predominantly CK7, 8, 18 and 19, and
lacking CK4 and 5 [27].
Other techniques rely on the differing sedimentation rates
for cells of different size and use a differential centrifuga-
tion technique for cell separation. This is carried out after
enzymatic dispersal of tissue fragments, the most efficient
being collagenase III [28]. First described by Emerman
and Wilkinson [29], this technique has been modified and
improved by our group and is a robust technique for short-
term culture of epithelial-enriched cells [30]. This tech-
nique allows propagation of sufficient quantities of cells
with defined phenotype suitable for subsequent cell and
molecular biology studies [30–32]. The method is outlined
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in Fig.1. It results in three individual fractions from the
tissue digest, termed organoid, epithelial and stromal.
The organoid fraction results from small fragments of
partly digested tissue, from which an outgrowth of cells is
observed (Fig.2a). Because this is an heterogeneous pop-
ulation, containing both epithelial and fibroblast cells, the
fibroblasts can outgrow the epithelial cells unless precau-
tion are taken. This is achieved by the use of a well
defined basal media that lacks serum. The main drawback
with this fraction, as with explant cultures, is that it may
give rise to a population of rapidly proliferating genetically
normal cells [30,33].
The epithelial fraction consists of predominantly single
cells with the classical cobblestone morphology seen in
epithelial cells (Fig.2b). With increasing time in selective
media, these cells can be expanded preferentially and
have been characterized by immunohistochemical, bio-
chemical and molecular biology techniques, as well as
flow cytometry [30–32]. The fibroblast fraction yields cells
with a bipolar spindle shape that is typical of fibroblasts
(Fig.2c) when cultured in media supplemented with heat-
inactivated foetal bovine serum, and they have also been
characterized using the techniques referred to above
[30–32].
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Figure 1
Breast tissue dispersal.
Breast
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Figure 2
Morphological appearance of the three cell fractions following
differential centrifugation followed by culture in selective medium. 
(a) Organoid fraction. The arrow illustrates a fragment of partially
digested tumour that attaches to the substrate of the culture vessel
and from which cells with an epithelial-like morphology migrate radially
and proliferate. (b) Epithelial fraction. (c) Stromal fraction consisting of
fibroblasts. Scale bar = 15µm.93
Following dispersal to single cells, immunomagnetic sepa-
ration has been used to specifically enrich populations of
cells from the normal mammary gland [34,35]. This uses
magnetic beads covalently coated with an antibody spe-
cific to the cell of interest, usually a surface marker. The
antibody-coated beads bind to cells that express the spe-
cific antigen, and they are extracted from the cell suspen-
sion by applying a magnet to the wall of the culture vessel
and then decanting any unbound cells. Despite its
success with normal mammary tissue, however, there are
no reports in the literature of its successful use to isolate
epithelial cells from breast tumours.
Pros and cons of breast primary culture
There are many benefits to be gained from using enriched
primary cultures. In some cases, cells are only maintained
in culture for a finite length of time, and they have little
opportunity to undergo the transformations that are seen
in the long-term culture of immortalized cell lines.
However, there is the possibility that cells isolated from a
breast tumour may behave differently in culture as com-
pared with their response when they are part of a
tissue/organ, because the cell–cell interactions that exist
in tissue are lost in vitro.
Primary culture does have limitations. These include slow
population doubling times and the finite lifespan before
senescence; often cells will only survive two or three pas-
sages. For some experimental techniques large numbers
of cells are required, which can sometimes be a limiting
factor because this often cannot be achieved until after
several passages. We are currently addressing this by
comparing the growth rate of primary epithelial cells in the
organoid medium we used originally [30] with keratinocyte
serum-free medium supplemented with bovine pituitary
extract and recombinant epidermal growth factor. When
cultured in the latter, cells appear to have an increased
growth rate and lifespan, as judged by an increase in initial
cell yield and the ability to undergo a greater number of
passages without appreciable change in phenotype
(Burdall SE, Speirs V, unpublished data). Furthermore, for
some tumours such as infiltrating grade I ductal carcino-
mas and tubular carcinomas, in which mitotic activity is
never or hardly ever evident in whole sections, it appears
likely that even use of an enrichment technique will not
provide an appropriate in vitro model, because the dou-
bling times would be so prolonged.
Another challenge faced by scientists trying to establish
cultures of breast tumour epithelial cells is possible conta-
mination by normal epithelial cells, because tumours are
heterogeneous. Phenotypically, there is no clear distinc-
tion between cultured tumour and normal epithelium with
the former easy to culture, even from tumours [16].
Because tumours are derived from lumenal epithelium,
immunopositivity for cytokeratin CK7, 8, 18 and 19 [36] is
often used to distinguish tumour from normal. CK19 has
proved particularly popular in this regard [27,30,32].
However, culture conditions can selectively influence cell
phenotype and CK19 expression can be induced in vitro,
even in normal mammary epithelial cells [16,37]. Thus, for
experiments conducted in low passage CK19+ cells pre-
sumed to be tumour cells, additional more robust markers
are essential (e.g. telomerase) [38].
Other culture methods
Although short-term culture of isolated tumour cells has, in
our hands, proved successful in a number of different labo-
ratory applications [30–32], it is still an imperfect model
because mechanical/enzymatic disaggregation disrupts the
normal tissue architecture and cell–cell communications
that clearly exist in vivo. One way to maintain these features
is the tissue slice method, which was originally described
for culture of breast and colon tumours [39]. This involves
preparing 400-µm thick tissue slices (thus allowing ade-
quate diffusion of nutrients from the culture medium) from
freshly excised tumour and placing them in vitro for up to
6 days, during which time cells continue to proliferate, as
judged by uptake of BrdU [39]. Afterward, the tissue can be
fixed and processed for immunohistochemistry and analysis
by light microscopy. Because of the fact that tissue archi-
tecture is maintained, this type of culture has obvious bene-
fits and it is proving particularly useful in studies of prostate
cancer (Maitland NJ, personal communication).
Other ways to recreate in vivo conditions are three-dimen-
sional culture systems, which allow the recombination of
epithelial and stromal cells usually in semisolid matrices
such as Matrigel [40–42]. The ability to culture stromal
cells independently from epithelial cells offers the possibil-
ity of these types of experiments, allowing the recreation,
under controlled conditions, of the cell interactions that
exist in vivo.
Successful breast primary culture has also been achieved
using irradiated feeder layers of NIH 3T3 cells [43]. The
rationale behind using feeder layers is that they allow
epithelial–mesenchymal interactions. Krasna and col-
leagues [43] reported growth of cells of luminal pheno-
type (as judged by expression of CK19) in 37/38 primary
tumour specimens following collagenase digestion of
tumour fragments and subsequent plating on 3T3 feeder
layers. Although they grew for 2–20 passages in vitro,
they were not found to be tumourigenic in nude mice,
casting doubt on their phenotype.
Ethical approval and tissue availability
A fundamental issue, which must be addressed before
considering using human clinical material for research, is
that of patient consent, which is now strictly controlled in
the UK following the Redfern report on organ retention
[44]. For therapeutic reasons, surgery always removes
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more than is necessary to diagnose; often, tumour excess
to that required for diagnosis and staging is left over. Pre-
viously considered ‘surgical waste’, it was relatively
straightforward to obtain this material fresh from a cooper-
ative breast surgeon and/or pathologist with the assump-
tion of implicit consent, but nowadays explicit patient
consent must always be sought. For this work to be a
success, the support of an enthusiastic collaborating
pathologist is also essential to provide the most macro-
scopically representative area of tumour. During the
course of our own research we have noticed that breast
tumours are becoming smaller through earlier diagnosis,
partly because of greater patient awareness and probably
also as a result of the UK Breast Screening Programme,
introduced in 1988, with national implementation by the
mid-1990s. The first priority must be given to pathological
diagnosis, and often this means that scientists are left with
increasingly smaller amounts of tumour for research.
However, because viable tumour cells can successfully be
isolated and expanded from a fine needle aspirate [45],
this need not be an issue. Indeed, in our experience suc-
cessful breast primary culture is due to a patient and
meticulous approach rather than directly proportional to
the amount of starting material.
Novel applications of primary culture for
translational research
There is considerable ethical pressure on scientists to
reduce or eliminate the use of animals in laboratory
research, and primary cell culture may be one way
forward, especially in preclinical drug testing. Another hot
area is to predict how patients will respond to chemother-
apy regimens. This has recently been addressed in the
extreme drug resistance assay, which involves culturing
viable tumour specimens in agarose for 5 days in the pres-
ence of chemotherapeutic drugs (for review [46]). Triti-
ated thymidine is then added for the final 48 hours and
liquid scintillation counting assesses the amount of
radioactive label that has been incorporated (indicative of
cell proliferation). This method has recently been piloted in
breast tumours. The technique was most successful when
tumours exceeded 1g, were of high grade, were from
younger patients and lacked expression of progesterone
receptor [47]. Overall, 70% of samples tested provided
information on chemotherapy resistance, suggesting that
selection of the most appropriate adjuvant therapy could
be guided by in vitro results.
A similar approach is the predictive 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium (MTT) assay, in which dis-
sected tumour biopsies of approximately 1mm3 are
cultured with chemotherapeutic drugs at concentrations
designed to mimic the plasma levels achieved in vivo [48].
The 50% inhibitory concentration is then calculated,
based on the conversion of MTT to formazan product.
Although further work was warranted, the preliminary con-
clusion from this study suggested that this was a feasible
approach in predicting response to chemotherapy. The
tissue slice method [39] described above also has poten-
tial here and is currently being evaluated by our group.
With the inevitable development of tumour-specific drugs
that are tailored to patient requirements, suitability and
gene profile, in future breast cancer will no longer be per-
ceived as one disease but rather as an individual entity on
a patient-specific basis.
The above techniques have tremendous potential in
selecting the most relevant adjuvant chemotherapy. This
can only be of benefit to the breast cancer patient, and
further trials in this area are warranted.
Conclusion
Because of their ease of use, there is no doubt that estab-
lished cell lines will continue to be used as models for
breast cancer. However, given the pitfalls discussed above,
it is essential that researchers understand their limitations
and take these into consideration when designing experi-
ments and interpreting results. Some of the more recently
established novel cell lines, particularly those established
from primary breast tumours and now available through
conventional cell line repositories, are worth considering as
research tools. Although more technically demanding to
establish, if it is properly characterized, primary culture
offers a more relevant clinical model of this disease that is
likely to provide more meaningful data. It also offers a better
route to cytogenetic analysis (e.g. using 24-colour fluores-
cent  in situ hybridization, which is notoriously difficult to
perform on solid tumours). With careful planning and con-
trolled experimentation, together these models will help to
enhance our understanding of breast cancer pathobiology.
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